Status:

COMPLETED

Gingival Crevicular Fluid Bone Morphogenetic Protein - 2 Release Profile Following the Use of Perforated Membrane

Lead Sponsor:

Al-Azhar University

Conditions:

Periodontal Pocket

Eligibility:

All Genders

31-51 years

Brief Summary

One of the most important elements suggested to be provided through membrane perforations to augment regeneration are cell released growth factors from the overlying periosteal and gingival cells. A d...

Detailed Description

The subjects were recruited consecutively from the list of patients seeking care for periodontal problems at the Department of Periodontology of the Faculty of Dental Medicine, Al Azhar University, Ca...

Eligibility Criteria

Inclusion

  • no systemic diseases which could influence the outcome of the therapy;
  • good compliance with the plaque control instructions following initial therapy;
  • teeth involved were all vital with score 0 mobility ;
  • each subject contributed matched pairs of two or three walled intrabony interproximal defects in premolar or molar teeth
  • the selected 2- or 3-wall intrabony defect depth ranged from 3-5 mm as detected in diagnostic periapical radiographs;
  • selected pocket depth (PD) ≥ 6 mm and clinical attachment level (CAL) ≥ 5 mm at the site of endosseous defect four weeks following initial cause-related therapy
  • endosseous radiographic defect angle ≤55 and ≥15
  • availability for the follow-up and maintenance program;
  • absence of periodontal treatment for the previous year;
  • absence of systemic medication or antibiotic treatment for the previous 6 months;
  • absence of a smoking habit and
  • absence of occlusal interferences.

Exclusion

  • Pregnant females were excluded from participating in the study.
  • Patients were also excluded from the study if they presented with opened interproximal contact, or inadequate compliance with the oral hygiene maintenance schedule.

Key Trial Info

Start Date :

March 1 2012

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2012

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT01860495

Start Date

March 1 2012

End Date

December 1 2012

Last Update

May 22 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Al azhar universty

Cairo Governorate, Egypt, Egypt, 1123

Gingival Crevicular Fluid Bone Morphogenetic Protein - 2 Release Profile Following the Use of Perforated Membrane | DecenTrialz